prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
Human Genome Project (HGP) A collaborative international scientific research project with the goal of sequencing all of the chromosomal DNA and identifying and mapping all of the genes within human cells, and ultimately of assembling a complete reference genome for the human species. The project was launched in 1990 by a consortium of federal agencies, universities, and research institutions and was declared complete in 2003. Because each individual human being has a unique genome, the finished reference genome is a mosaic of sequences obtained by sampling DNA from thousands of individuals across the world and does not represent any one individual.
The peptide bonds in the chain are polar, i.e. they have separated positive and negative charges (partial charges) in the carbonyl group, which can act as hydrogen bond acceptor and in the NH group, which can act as hydrogen bond donor. These groups can therefore interact in the protein structure. Proteins consist mostly of 20 different types of L-α-amino acids (the proteinogenic amino acids). These can be classified according to the chemistry of the side chain, which also plays an important structural role. Glycine takes on a special position, as it has the smallest side chain, only one hydrogen atom, and therefore can increase the local flexibility in the protein structure. Cysteine in contrast can react with another cysteine residue to form one cystine and thereby form a cross link stabilizing the whole structure. Protein structure arises from a sequence of secondary structure elements, such as α helices and β sheets. In secondary structures, regular patterns of H-bonds are formed between the main chain NH and CO groups of spatially neighboring amino acids, and the amino acids have similar Φ and ψ angles.
Normally, Hagen–Poiseuille flow implies not just the relation for the pressure drop, above, but also the full solution for the laminar flow profile, which is parabolic. However, the result for the pressure drop can be extended to turbulent flow by inferring an effective turbulent viscosity in the case of turbulent flow, even though the flow profile in turbulent flow is strictly speaking not actually parabolic. In both cases, laminar or turbulent, the pressure drop is related to the stress at the wall, which determines the so-called friction factor. The wall stress can be determined phenomenologically by the Darcy–Weisbach equation in the field of hydraulics, given a relationship for the friction factor in terms of the Reynolds number. In the case of laminar flow, for a circular cross section:
==== Monitoring ==== The therapeutic target range TSH level for patients on treatment ranges between 0.3 and 3.0 μIU/mL. For hypothyroid patients on thyroxine, measurement of TSH alone is generally considered sufficient. An increase in TSH above the normal range indicates under-replacement or poor compliance with therapy. A significant reduction in TSH suggests over-treatment. In both cases, a change in dose may be required. A low or low-normal TSH value may also signal pituitary disease in the absence of replacement. For hyperthyroid patients, both TSH and T4 are usually monitored. In pregnancy, TSH measurements do not seem to be a good marker for the well-known association of maternal thyroid hormone availability with offspring neurocognitive development. TSH distribution progressively shifts toward higher concentrations with age.
Sources: en.wikipedia.org
== Description == It is a perennial, with a typical growth height of 50–120 cm. Like most other members of the carrot family, it produces large umbels of white flowers and has dissected leaves. Angelica keiskei closely resembles Angelica japonica, but can be distinguished by its blooming period, which lasts from May to October, whereas A. japonica's blooming period lasts only between May and July. Another indicator is the characteristic color of its sap.
== Further reading == Adams E (1954). "Enzymatic synthesis of histidine from histidinol". J. Biol. Chem. 209 (2): 829–846. doi:10.1016/S0021-9258(18)65512-7. PMID 13192138. Adams E (1955). "L-Histidinal, a biosynthetic precursor of histidine". J. Biol. Chem. 217 (1): 325–344. doi:10.1016/S0021-9258(19)57184-8. PMID 13271397. Yourno J, Ino I (1968). "Purification and crystallization of histidinol dehydrogenase from Salmonella typhimurium LT-2". J. Biol. Chem. 243 (12): 3273–6. doi:10.1016/S0021-9258(18)93303-X. PMID 4872177. Loper JC (1968). "Histidinol dehydrogenase from Salmonella typhimurium Crystallization and composition studies". J. Biol. Chem. 243 (12): 3264–72. doi:10.1016/S0021-9258(18)93302-8. PMID 4872176.
Territories on both sides of the new Polish-Ukrainian border were also "ethnically cleansed". Of the Ukrainians and Lemkos living in Poland within the new borders (about 700,000), close to 95% were forcibly moved to the Soviet Ukraine, or (in 1947) to the new territories in northern and western Poland under Operation Vistula. In Volhynia, 98% of the Polish pre-war population was either killed or expelled; in Eastern Galicia, the Polish population was reduced by 92%. According to Timothy D. Snyder, about 70,000 Poles and about 20,000 Ukrainians were killed in the ethnic violence that occurred in the 1940s, both during and after the war. According to an estimate by historian Jan Grabowski, about 50,000 of the 250,000 Polish Jews who escaped the Nazis during the liquidation of ghettos survived without leaving Poland (the remainder perished). More were repatriated from the Soviet Union and elsewhere, and the February 1946 population census showed about 300,000 Jews within Poland's new borders.[e] Of the surviving Jews, many chose to emigrate or felt compelled to because of the anti-Jewish violence in Poland. Because of changing borders and the mass movements of people of various nationalities, the emerging communist Poland ended up with a mainly homogeneous, ethnically Polish population (97.6% according to the December 1950 census). The remaining members of ethnic minorities were not encouraged, by the authorities or by their neighbors, to emphasize their ethnic identities.[i][a1]
Resistance has in fact appeared and may be growing. But it is remarkable that despite the sharp shifts in the distribution of power, the other great powers have not yet responded in a way anticipated by balance-of-power theory.
Sources: en.wikipedia.org
==== Intracellular receptors ==== Intracellular and nuclear receptors are a direct way for the cell to respond to internal changes and signals. Intracellular receptors are activated by hydrophobic ligands that pass through the cellular membrane. All nuclear receptors are very similar in structure, and are described with intrinsic transcriptional activity. Intrinsic transcriptional involves the three following domains: transcription-activating, DNA-binding, and ligand-binding. These domains and ligands are hydrophobic and are able to travel through the membrane. The movement of macromolecules and ligand molecules into the cell enables a complex transport system of intracellular signal transfers through different cellular environments until response is enabled. Nuclear receptors are a special class of intracellular receptor that specifically aid the needs of the cell to express certain genes. Nuclear receptors often bind directly to DNA by targeting specific DNA sequences in order to express or repress transcription of nearby genes.
=== Enamels === During the Meiji era, Japanese cloisonné enamel reached a technical peak, producing items more advanced than any that had existed before. The period from 1890 to 1910 was known as the "Golden age" of Japanese enamels. Artists experimented with pastes and with the firing process to produce ever larger blocks of enamel, with less need for cloisons (enclosing metal strips). During this period, enamels with a design unique to Japan, in which flowers, birds and insects were used as themes, became popular. Designs also increasingly used areas of blank space. The two most famous enamelers of this era were Namikawa Yasuyuki and Namikawa Sōsuke, whose family names sound the same but who were not related. Namikawa Sōsuke promoted his work as technically innovative and adopted a style resembling fine paintings. Namikawa Yasuyuki was more conservative, opting for geometrical patterns but gradually becoming more pictorial during his career. Along with the two Namikawa, the Ando Cloisonné Company has produced many high-quality cloisonné works. Namikawa Yasuyuki's Vase with Birds and Flowers of the Four Seasons is one of the finest examples of cloisonné from this era. It won a gold medal at the 1900 Paris Exposition and was designated as an Important Cultural Property in 2025.
=== Immune function === Vitamin A plays an important role in the body's immune function, both the adaptive response, and to help the body fight off infection. The anti-inflammatory effects of vitamin A also contribute to repairing mucosal cells that can be damaged by an infection. For these reasons, there have been quite a few studies looking at the potential role that Vitamin A supplementation may play in improving an immune response or to helping the body fight off an infection. The evidence supporting vitamin A supplementation for children under the age of 7 years to prevent upper respiratory tract infections is weak, and the weak evidence from low-quality clinical trials does not support vitamin A as being effective or having a benefit. More research is needed to consider different doses, the ages and populations of people who may potentially benefit, and the length of treatment.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.